Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause.
MenopauseSep 1, 2026 (epub)
Antonia Morga, Ting-An Tai, Ritika Kapoor et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial assessed the effects of fezolinetant on work productivity and indirect costs in women with moderate to severe vasomotor symptoms (VMS) associated with menopause. The study found that fezolinetant improved work productivity, with a reduction in overall productivity loss of -12.4% compared to placebo, and resulted in significant annualized cost savings across multiple countries.
Key findings
- Fezolinetant improved work productivity by 2.8 to 4.2 weekly work hours per woman compared to placebo.
- Annualized cost savings per woman with fezolinetant were 7,791 USD in the United States.
- Overall work productivity loss decreased by -12.4% in the fezolinetant group versus placebo.
- In hormone therapy-unsuitable women, productivity loss improved by -10.2% with fezolinetant.
Why it matters
Improving work productivity and reducing indirect costs are crucial for women experiencing VMS, particularly those who cannot use hormone therapy. This study highlights the potential economic benefits of fezolinetant as a treatment option.